PRESS RELEASE
News
-
-
PRESS RELEASE
First half of the financial year 2024/25: Strong organic growth and margin expansion continue – strategy execution on track
dormakaba Holding AG reports strong organic growth and margin expansion in the first half of the financial year 2024/25. The company's strategy execution is on track -
PRESS RELEASE
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®. Approval for treating retinal diseases granted by UK's MHRA -
-
PRESS RELEASE
UniDoc - Announces Filing of Amended and Restated Interim Management Discussion and Analysis
UniDoc Health Corp. issues amended and restated management's discussion and analysis for clarifying disclosure following continuous disclosure review by the British Columbia Securities Commission -
-
PRESS RELEASE
Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile
Onco-Innovations Limited announces successful preclinical study results of its second-generation nanoparticle formulation of PNKP Compound, showing enhanced inhibitor delivery with minimal toxicity for potential cancer therapy -
PRESS RELEASE
Kingstone Announces Record Operating Profit and Growth for Fourth Quarter and Full Year 2024
Kingstone Companies, Inc. schedules conference call on March 14 for fourth quarter 2024 financial results. Company's preliminary financial performance highlights significant improvements in direct written premiums and operating income -
PRESS RELEASE
Sanofi: Disclosure of trading in own shares
-
